Exai Bio Launches Generative AI Liquid Biopsy Platform Highlighted in Nature Communications.
11/21/24, 10:34 PM
Location
palo altoIndustry
biotechnology
science and engineering
software
Exai Bio has announced a peer-reviewed publication that demonstrates the superior performance of its generative AI liquid biopsy model in detecting early-stage lung cancer. The publication highlights how Exai's platform outperforms traditional machine learning methods in sensitivity and specificity.
Company Info
Location
palo alto, california, united states
Additional Info
Exai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company’s proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer.